Full Press Release Details
Inspira Technologies is Developing the VORTXTM
Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide
Total addressable market is currently estimated at $1.16 billion
Ra'anana, Israel, May 11, 2023 - Inspira Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to
revolutionize acute respiratory care, today announced the development of the VORTXTM Blood Oxygenator, an Augmented Respiration
Technology based on a new breakthrough technological approach, being designed with the intent to imitate the function of the lung, by
efficiently saturating the blood with oxygen and removing carbon dioxide.
The VORTXTM Blood Oxygenator, which is under development,
has the potential to revolutionize the perfusionists systems market, currently valued at $1.16 billion in 20231, targeting
~2 million extracorporeal procedures performed annually including open-heart surgeries and extracorporeal membrane oxygenation ("ECMO")
treatment2. The Company anticipates that this market segment may grow substantially with the additional market opportunity
represented by the new treatment category potentially created by our flagship INSPIRATM ART.
The VORTXTM Blood Oxygenator is being designed to improve
hemodynamic performance and reduce oxygenator failure. The current blood oxygenator market3 is based upon hollow fiber membrane
technology, associated with medical complications including device failure, coagulation (clotting) and hemolysis (damage or destruction
of red blood cells), which induces risks and impacts patient outcomes.
The VORTXTM Blood Oxygenator is being developed as an independent
stand-alone disposable unit that will also be compatible with our flagship INSPIRATM ART system and ALICETM device.
Upon completion of development and testing of the VORTXTM Blood Oxygenator, the unit is expected is to be submitted to the
U.S. Food and Drug Administration (FDA) for regulatory review and approval.
Dr. Daniella Yeheskely-Hayon, Inspira Technologies' Chief Technology
"Having vast experience in blood oxygenation development, my
team and I are excited to lead the development of the revolutionary VORTXTM Blood Oxygenator. Inspira Technologies' highly
advanced testing laboratories are the core to the development of this new technological approach. Currently, available blood oxygenators
on the market are based on the same hollow fiber membrane technology. Our VORTX focuses on a totally new technological approach."
About Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRATM
ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any
regulatory entity. For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the development of the VORTXTM Blood Oxygenator; the potential benefits of the VORTXTM Blood Oxygenator,
including the potential to revolutionize the oxygenator industry and market, the potential market size of extracorporeal procedures open-heart
surgeries and ECMO treatment that may be targeted by this technology; the expected market opportunity for the VORTXTM Blood
Oxygenator; and the expected growth of the global oxygenator market. These forward-looking statements and their implications are based
solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties
affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for
the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available
on the SEC's website, www.sec.gov
US Public Relations and Investor Relations
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
This technology has not been tested or used in humans and is subject
to regulatory approval.